Robert P Eury, 634141 Excelsior Rd, Eureka, CA 95503

6530950, Mar 11, 2003

Aug 3, 2000

09/632482

Angelica Alvarado - Santa Clara CA
Robert Eury - Cupertino CA
Irina D. Pomerantseva - Mountain View CA
Michael Froix - Mountain View CA

Quanam Medical Corporation - Santa Clara CA

A61F 206

623 113, 623 1, 623 12, 623 116, 623 12, 623 142, 623 146, 526319, 526320, 5263231, 526329, 5263292, 5263295

A stent for insertion into a lumen, having rigid regions and flexible regions along its length, and one or more polymer members coaxially disposed about the outer surface of the stent The polymer members are positioned over the rigid regions of the support stent, while the flexible regions are uncovered and free of polymer members, wherein the polymer members are radially expandable with the support stent.

6653426, Nov 25, 2003

Dec 26, 2002

10/330517

Angelica Alvarado - Santa Clara CA
Robert Eury - Cupertino CA
Irina D. Pomerantseva - Mountain View CA
Michael Froix - Mountain View CA

Quanam Medical Corporation - Santa Clara CA

C08F11806

526319, 526320, 5263231, 526329, 5263292, 5263295, 526321, 623 12, 623 112, 623 116, 623 142, 623 146

A polymer composition for use in forming a stent is described. The composition includes a monomer of an aliphatic ester of acrylic acid which has a glass transition temperature less than 25Â C. and a second monomer that copolymerizes with the first monomer and which has a glass transition temperature greater than 25Â C. The components in the composition are mixed in amounts suitable to give a copolymer having a glass transition temperature less than 25Â C. , or in case of block copolymers, having at least one glass transition temperature less than 25Â C. A stent including polymer members formed from the described composition is also disclosed.

7115691, Oct 3, 2006

Sep 24, 2003

10/670035

Angelica Alvarado - Santa Clara CA, US
Robert Eury - Cupertino CA, US
Irina D. Pomerantseva - Mountain View CA, US
Michael Froix - Mountain View CA, US

Quanam Medical Corporation - Santa Clara CA

C08F 18/20

526245, 526319, 526320, 5263231, 5263285, 5263292, 5263296, 623 113, 623 114, 623 116, 623 12, 623 142, 623 146

A polymer composition for use in forming a stent is described. The composition includes a monomer of an aliphatic ester of acrylic acid which has a glass transition temperature less than 25 C. and a second monomer that copolymerizes with the first monomer and which has a glass transition temperature greater than 25 C. The components in the composition are mixed in amounts suitable to give a copolymer having a glass transition temperature less than 25 C. , or in case of block copolymers, having at least one glass transition temperature less than 25 C. A stent including polymer members formed from the described composition is also disclosed.

7338511, Mar 4, 2008

May 24, 2002

10/155563

Gregory E. Mirigian - Dublin CA, US
Huey Quoc Chan - San Jose CA, US
Thomas Yung-Hui Chien - San Jose CA, US
Stephen C. Porter - Fremont CA, US
Robert P. Eury - Cupertino CA, US

Boston Scientific-Scimed, Inc. - Maple Grove MN

A61M 29/00

606200

A solid embolic material that is capable of filling irregularly shaped and asymmetrical vascular defects in a controlled and predictable manner, without the difficulties associated with delivery of the embolic material through a microcatheter and containment of the embolic material in a defect. A detachable embolic balloon with optional check valve for maintaining liquid in the balloon prior to curing and optional multi-leaflet covering to prevent the balloon from expanding into the native vascular lumen.

7374570, May 20, 2008

Sep 15, 2006

11/522372

Angelica Alvarado - Santa Clara CA, US
Robert Eury - Cupertino CA, US
Irina D. Pomerantseva - Mountain View CA, US
Michael Froix - Mountain View CA, US

Quanam Medical Corporation - Santa Clara CA

A61F 2/06
C08F 118/02

623 114, 623 113, 623 116, 623 12, 623 142, 623 146, 526245, 526319, 526320, 5263231, 5263285, 5263292, 5263296

A polymer composition for use in forming a stent is described. The composition includes a monomer of an aliphatic ester of acrylic acid which has a glass transition temperature less than 25 C. and a second monomer that copolymerizes with the first monomer and which has a glass transition temperature greater than 25 C. The components in the composition are mixed in amounts suitable to give a copolymer having a glass transition temperature less than 25 C. , or in case of block copolymers, having at least one glass transition temperature less than 25 C. A stent including polymer members formed from the described composition is also disclosed.

RE44763, Feb 11, 2014

Feb 1, 2002

10/061458

Linh A. Dinh - Santa Clara CA, US
Loc X. Phan - San Jose CA, US
Robert Eury - Cupertino CA, US
Irina Pomerantseva - Wakefield MA, US
Michael Froix - Mountain View CA, US

Boston Scientific Scimed, Inc. - Maple Grove MN

A61F 2/06

623 115

A unit cell for use in a medical device, such as a stent, is disclosed along with a description of a stent formed from a plurality of unit cells and for use in the treatment of restenosis or other vascular narrowing. The unit cell is designed and configured for uniform radial expansion with minimal axial shortening and recoil, and is selectively variable in flexibility and expendability.

2002000, Jan 10, 2002

May 25, 2001

09/866029

Robert Eury - Cupertino CA, US
Angelica Alvarado - Santa Clara CA, US
Irina Pomerantseva - Mountain View CA, US
Michael Froix - Mountain View CA, US

Quanam Medical Corporation

A61F002/06

623/001150, 623/001420

A method of inhibitng cellular proliferation associated with a hyperproliferative condition, such as restenosis, is described. The method includes administering a topoisomerase inhibitor. A stent for local administration of the topoisomerase inhibitor is also described.

5871436, Feb 16, 1999

Jul 19, 1996

8/685447

Robert P. Eury - Cupertino CA

Advanced Cardiovascular Systems, Inc. - Santa Clara CA

A61N 500

600 3

An implantable medical device is used to deliver a dosage of radiation to a localized site within a patient. The device is coated with a chelator selected for its bonding affinity with a specific radioisotope. A base layer and optionally a spacer layer is first applied to the device to provide a proper foundation for the chelator. Just prior to implantation, the device is immersed in a solution of the radioisotope which enables a preselected amount of such radioisotope to be adsorbed.